studies

la/mBC - HER2 positive - 1st Line (L1), pertuzumab based treatment vs. all, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsCLEOPATRA, 2012 0.66 [0.52; 0.84] 0.66[0.52; 0.84]CLEOPATRA, 201210%808NAnot evaluable deaths (OS) (extension)detailed resultsCLEOPATRA, 2012 0.69 [0.58; 0.82] 0.69[0.58; 0.82]CLEOPATRA, 201210%808NAnot evaluable PFS (extension)detailed resultsCLEOPATRA, 2012 0.69 [0.59; 0.81] 0.69[0.59; 0.81]CLEOPATRA, 201210%808NAnot evaluable progression or deaths (PFS)detailed resultsCLEOPATRA, 2012 0.62 [0.51; 0.75] 0.62[0.51; 0.75]CLEOPATRA, 201210%808NAnot evaluable objective responses (ORR)detailed resultsCLEOPATRA, 2012 10.80 [5.29; 22.05] 10.80[5.29; 22.05]CLEOPATRA, 201210%679NAnot evaluable0.220.01.0relative treatment effectwww.metaEvidence.org2024-05-18 20:28 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 146 - treatments: 368,1301,1412,1298

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons